Bone remodeling in rheumatic disease: A question of balance

Immunological Reviews

Volumn 233, Issue 1, 2010, Pages 301-312

  Walsh, Nicole C ^a   Gravallese, Ellen M ^b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Inflammation; Osteoprotegerin; RANKL; Rheumatoid arthritis; Spondyloarthropathy; Wnt

Indexed keywords

DENOSUMAB; DICKKOPF 1 PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOPROTEIN GP 130; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 17; INTERLEUKIN 6; METHOTREXATE; ONCOSTATIN M; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TOCULIZUMAB; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT1 PROTEIN; ZOLEDRONIC ACID;

ARTHRITIS; BONE ATROPHY; BONE EROSION; BONE REMODELING; CELL DIFFERENTIATION; CELL FUNCTION; CELL TYPE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; NONHUMAN; OSSIFICATION; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SPONDYLOARTHROPATHY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE REMODELING; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; JOINTS; OSTEOBLASTS; OSTEOCLASTS; SIGNAL TRANSDUCTION; SPONDYLARTHROPATHIES; WNT PROTEINS;

EID: 73249137735     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2009.00857.x     Document Type: Review

References (145)

1. Stewart A, Mackenzie LM, Black AJ, Reid DM. Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radiogrammetry: a pilot study. Rheumatology 2004 43 : 1561 1564.
2. Joffe I, Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 1991 20 : 256 272.
3. Peel NF, Eastell R, Russell RGG. Osteoporosis in rheumatoid arthritis - the laboratory perspective. Br J Rheum 1991 30 : 84 85.
4. Woolf AD. Osteoporosis in rheumatoid arthritis - the clinical viewpoint. Br J Rheum 1991 30 : 82 84.
5. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology 2000 39 (Suppl 24 29.
6. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984 27 : 968 975. (Pubitemid 14004758)
7. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998 152 : 943 951.
8. Gravallese EM, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000 43 : 250 258.
9. Kuratani T, Nagata K, Kukita T, Hotokebuchi T, Nakasima A, Iijima T. Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol Histopathol 1998 13 : 751 759.
10. Suzuki Y, Nishikaku F, Nakatuka M, Koga Y. Osteoclast-like cells in murine collagen induced arthritis. J Rheumatol 1998 25 : 1154 1160.
11. Romas E, et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000 43 : 821 826.
12. Pettit AR, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001 159 : 1689 1699.
13. Keffer J, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991 10 : 4025 4031.
14. Shealy DJ, et al. Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res 2002 4 : R7.
15. Redlich K, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002 110 : 1419 1427.
16. Schett G, et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003 48 : 2042 2051.
17. Herrak P, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 2004 50 : 2327 2337.
18. Sims NA, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 2004 50 : 2338 2346.
19. Jarrett SJ, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006 54 : 1410 1414.
20. Yasuda H, et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999 25 : 109 113.
21. Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 : 165 176.
22. Kong YY, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999 402 : 304 309.
23. Dougall WC, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999 13 : 2412 2424.
24. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem 1998 273 : 28355 28359.
25. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008 473 : 139 146.
26. Takayanagi H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002 3 : 889 901.
27. Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP. NFATc1 directly induces the human beta3 integrin gene in osteoclast differentiation. J Musculoskelet Neuronal Interact 2005 5 : 335 337.
28. Crotti TN, et al. PU.1 and NFATc1 mediate osteoclastic induction of the mouse beta3 integrin promoter. J Cell Physiol 2008 215 : 636 644.
29. Shen Z, Crotti TN, Flannery MR, Matsuzaki K, Goldring SR, McHugh KP. A novel promoter regulates calcitonin receptor gene expression in human osteoclasts. Biochim Biophys Acta 2007 1769 : 659 667.
30. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998 139 : 4743 4746.
31. Kotake S, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001 44 : 1003 1012.
32. Takayanagi H, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000 43 : 259 269.
33. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 2001 40 : 623 630.
34. Crotti TN, et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002 61 : 1047 1054.
35. Haynes DR, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 2003 42 : 123 134.
36. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology 2006 45 : 1068 1076.
37. Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum 2008 58 : 718 729.
38. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 2004 19 : 207 213.
39. Redlich K, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002 46 : 785 792.
40. Romas E, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002 161 : 1419 1427.
41. Bolon B, Campagnuolo G, Feige U. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell Mol Life Sci 2002 59 : 1569 1576. (Pubitemid 35239311)
42. Campagnuolo G, Bolon B, Feige U. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 2002 46 : 1926 1936.
43. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001 16 : 348 360.
44. Cohen SB, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008 58 : 1299 1309.
45. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 397 : 315 323.
46. Komori T, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997 89 : 755 764.
47. Nakashima K, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002 108 : 17 29.
48. Lian JB, Stein GS, Aubin JE. Bone formation: maturation and functional activities of osteoblast lineage cells. In : Favus MJ ed. Primer on the Metabolic Bone Diseases and Disorder of Mineral Metabolism. 5th edn. Washington, DC : American Society for Bone and Mineral Research, 2003 : 13 28.
49. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000 141 : 4768 4776.
50. Atkins GJ, et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003 18 : 1088 1098.
51. Feldmann M, et al. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found Symp 2004 73 : 106 111.
52. Rau R, Herborn G. Healing phenomena of erosive changes in rheumatoid arthritis patients undergoing disease-modifying antirheumatic drug therapy. Arthritis Rheum 1996 39 : 162 168.
53. Sokka T, Hannonen P. Healing of erosions in rheumatoid arthritis. Ann Rheum Dis 2000 59 : 647 649.
54. Rau R, Wassenberg S, Herborn G, Perschel WT, Freitag G. Identification of radiologic healing phenomena in patients with rheumatoid arthritis. J Rheumatol 2001 28 : 2608 2615.
55. Wassenberg S, Rau R. Radiographic healing with sustained clinical remission in a patient with rheumatoid arthritis receiving methotrexate monotherapy. Arthritis Rheum 2002 46 : 2804 2807.
56. Rau R, Sander O, Wassenberg S. Erosion healing in rheumatoid arthritis after anakinra treatment. Ann Rheum Dis 2003 62 : 671 673.
57. Sharp JT, et al. Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. J Rheumatol 2003 30 : 1102 1107.
58. Van Der Heijde D, Sharp JT, Rau R, Strand V. OMERACT workshop: repair of structural damage in rheumatoid arthritis. J Rheumatol 2003 30 : 1108 1109.
59. Ideguchi H, Ohno S, Hattori H, Senuma A, Ishigatsubo Y. Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs. Arthritis Res Ther 2006 8 : R76.
60. Rau R. Is remission in rheumatoid arthritis associated with radiographic healing? Clin Exp Rheumatol 2006 24 (Suppl S-41 S-44.
61. Walsh NC, et al. Osteoblast function is compromised at sites of focal bone erosion in rheumatoid arthritis. J Bone Miner Res 2009 24 : 1572 1585.
62. Schett G, et al. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 2005 52 : 1604 1611.
63. Gortz B, et al. Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation. J Bone Miner Res 2004 19 : 990 998.
64. Zwerina J, Tuerk B, Redlich K, Smolen JS, Schett G. Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: direct analysis of bone turnover in murine arthritis. Arthritis Res Ther 2006 8 : R22.
65. Jimenez-Boj E, et al. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 2005 175 : 2579 2588.
66. Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005 208 : 228 251.
67. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008 118 : 3537 3545.
68. Segal B, Rhodus NL, Patel K. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008 106 : 778 787.
69. Li P, et al. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum 2004 50 : 265 276.
70. Kitaura H, et al. Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. J Immunol 2004 173 : 4838 4846.
71. Canalis E. Effects of tumor necrosis factor on bone formation in vitro. Endocrinology 1987 121 : 1596 1604. (Pubitemid 18012760)
72. Centrella M, McCarthy TL, Canalis E. Tumor necrosis factor-alpha inhibits collagen synthesis and alkaline phosphatase activity independently of its effect on deoxyribonucleic acid synthesis in osteoblast-enriched bone cell cultures. Endocrinology 1988 123 : 1442 1448.
73. Li YP, Stashenko P. Proinflammatory cytokines tumor necrosis factor-alpha and IL-6, but not IL-1, down-regulate the osteocalcin gene promoter. J Immunol 1992 148 : 788 794.
74. Panagakos FS, Hinojosa LP, Kumar S. Formation and mineralization of extracellular matrix secreted by an immortal human osteoblastic cell line: modulation by tumor necrosis factor-alpha. Inflammation 1994 18 : 267 284.
75. Kuroki T, Shingu M, Koshihara Y, Nobunaga M. Effects of cytokines on alkaline phosphatase and osteocalcin production, calcification and calcium release by human osteoblastic cells. Br J Rheumatol 1994 33 : 224 230.
76. Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 2003 321 : 1 15.
77. Gilbert L, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 2002 277 : 2695 2701.
78. Kaneki H, et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 2006 281 : 4326 4333.
79. Panagakos FS, Fernandez C, Kumar S. Ultrastructural analysis of mineralized matrix from human osteoblastic cells: effect of tumor necrosis factor-alpha. Mol Cell Biochem 1996 158 : 81 89.
80. Redlich K, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 2004 164 : 543 555.
81. Ji H, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 2002 196 : 77 85.
82. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005 115 : 282 290.
83. Zwerina J, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007 104 : 11742 11747.
84. Kotake S, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996 11 : 88 95.
85. Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006 54 : 158 168.
86. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology 2008 47 : 1635 1640.
87. Fonseca JE, Santos MJ, Canhao H, Choy E Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009 8 : 538 542.
88. Fujimoto M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008 58 : 3710 3719.
89. Mihara M, Ohsugi Y, Kishimoto T. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody. Biofactors 2009 35 : 47 51.
90. Nowell MA, et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 2009 182 : 613 622.
91. Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki M. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol 2008 84 : 262 270.
92. Jones G, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2009 DOI
93. Koenders MI, et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 2005 52 : 3239 3247.
94. Koenders MI, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005 167 : 141 149.
95. Joosten LA, et al. T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum 2008 58 : 98 108.
96. Koenders MI, et al. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 2008 58 : 3461 3470.
97. Ogura H, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008 29 : 628 636.
98. Kotake S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999 103 : 1345 1352.
99. Lubberts E, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003 170 : 2655 2662.
100. Hwang SY, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 2004 6 : R120 R128.
101. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003 18 : 1842 1853.
102. Gong Y, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001 107 : 513 523.
103. Boyden LM, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002 346 : 1513 1521.
104. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004 5 : 691 701.
105. Kulkarni NH, et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 2006 21 : 910 920.
106. Holmen SL, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005 280 : 21162 21168.
107. Glass DA, 2nd., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005 8 : 751 764.
108. Jackson A, et al. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 2005 36 : 585 598.
109. Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007 13 : 4042 4045.
110. Sen M, Chamorro M, Reifert J, Corr M, Carson DA. Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum 2001 44 : 772 781.
111. Tian E, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003 349 : 2483 2494.
112. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006 108 : 3992 3996.
113. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD, Jr.,. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007 109 : 2106 2111.
114. Qiang YW, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008 112 : 196 207.
115. Oshima T, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005 106 : 3160 3165.
116. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2004 318 : 259 264.
117. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005 329 : 177 181.
118. Wang FS, et al. Secreted Frizzled-related protein 1 (SFRP1) modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 2005 146 : 2415 2423.
119. Bodine PV, Komm BS. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 2006 7 : 33 39.
120. Ijiri K, et al. Differential expression patterns of secreted frizzled related protein genes in synovial cells from patients with arthritis. J Rheumatol 2002 29 : 2266 2270.
121. Diarra D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007 13 : 156 163.
122. Schett G. Joint remodelling in inflammatory disease. Ann Rheum Dis 2007 66 (Suppl iii42 iii44.
123. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 2007 282 : 27298 27305.
124. Colla S, et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 2007 109 : 4470 4477.
125. Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2005 17 : 293 298.
126. Etherington PJ, Winlove P, Taylor P, Paleolog E, Miotla JM. VEGF release is associated with reduced oxygen tensions in experimental inflammatory arthritis. Clin Exp Rheumatol 2002 20 : 799 805.
127. Arnett TR, et al. Hypoxia is a major stimulator of osteoclast formation and bone resorption. J Cell Physiol 2003 196 : 2 8.
128. Utting JC, Robins SP, Brandao-Burch A, Orriss IR, Behar J, Arnett TR. Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Exp Cell Res 2006 312 : 1693 1702.
129. Brandao-Burch A, Utting JC, Orriss IR, Arnett TR. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif Tissue Int 2005 77 : 167 174.
130. Lories RJ, et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice. Arthritis Rheum 2007 56 : 4095 4103.
131. Zi X, et al. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 2005 65 : 9762 9770.
132. Banyai L, Patthy L. The NTR module: domains of netrins, secreted frizzled related proteins, and type I procollagen C-proteinase enhancer protein are homologous with tissue inhibitors of metalloproteases. Protein Sci 1999 8 : 1636 1642.
133. Hausler KD, et al. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res 2004 19 : 1873 1881.
134. McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007 56 : 2482 2491.
135. Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat 2001 199 : 503 526.
136. McGonagle D, Benjamin M, Marzo-Ortega H, Emery P. Advances in the understanding of entheseal inflammation. Curr Rheumatol Rep 2002 4 : 500 506.
137. Benjamin M, Moriggl B, Brenner E, Emery P, McGonagle D, Redman S. The "enthesis organ" concept: why enthesopathies may not present as focal insertional disorders. Arthritis Rheum 2004 50 : 3306 3313.
138. McGonagle D. Imaging the joint and enthesis: insights into pathogenesis of psoriatic arthritis. Ann Rheum Dis 2005 64 (Suppl ii58 ii60.
139. Benjamin M, McGonagle D. Histopathologic changes at "synovio- entheseal complexes" suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis. Arthritis Rheum 2007 56 : 3601 3609.
140. Benjamin M, Toumi H, Suzuki D, Redman S, Emery P, McGonagle D. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum 2007 56 : 224 233.
141. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005 115 : 1571 1579.
142. Lories RJ, et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum 2006 54 : 1736 1746.
143. Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007 56 : 489 497.
144. Lories RJ, Derese I, Luyten FP. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis. Rheumatology 2008 47 : 605 608.
145. Uderhardt S, et al. Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2009 DOI :.